CLINICAL TRIAL

COVID Convalescent Plasma for COVID-19

High Risk
Recruiting · 18+ · All Sexes · Jackson, MS

This study is evaluating whether a transfusion of plasma from people who have recovered from a severe respiratory illness may help treat individuals with severe respiratory illness.

See full description

About the trial for COVID-19

Treatment Groups

This trial involves 2 different treatments. COVID Convalescent Plasma is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase < 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
COVID Convalescent Plasma
BIOLOGICAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
COVID-19 convalescent plasma
Not yet FDA approved

Eligibility

This trial is for patients born any sex aged 18 and older. There are 8 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Age ≥ 18
The patient has been confirmed to have SARS-CoV-2 infection through laboratory testing. show original
Hypoxia (PaO2/FiO2 <300, Pulse oximetry <93% at rest
in a 55-year-old man with chronic obstructive pulmonary disease A 55-year-old man was found to have evidence of pulmonary infiltration on a chest x-ray show original
Respiratory failure
Sepsis
Multiple organ dysfunction or failure (assessed by SOFA score)
is required before a medical procedure, other than in an emergency, can be started show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Days 1, 3, 7, and 28
Screening: ~3 weeks
Treatment: Varies
Reporting: Days 1, 3, 7, and 28
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Days 1, 3, 7, and 28.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether COVID Convalescent Plasma will improve 5 primary outcomes and 6 secondary outcomes in patients with COVID-19. Measurement will happen over the course of 3 Days.

Change in aO2 after CCP transfusion.
3 DAYS
Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by aO2.
3 DAYS
Change in respiratory rate after CCP transfusion.
3 DAYS
Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by respiratory rate.
3 DAYS
Change in PaO2/FiO2 after CCP transfusion.
3 DAYS
Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by PaO2/FiO2.
3 DAYS
Change in pulse oximetry status after CCP transfusion.
3 DAYS
Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by pulse oximetry.
3 DAYS
Change in intubation status after CCP transfusion.
3 DAYS
Change in pre-transfusion respiratory status compared to Day 3 respiratory status measured by intubation status.
3 DAYS
Development of immune complex disorders.
DAYS 1, 3, 7, AND 28
Presence of any signs or symptoms of immune complex disorders (fever spike, urticarial lesion, arthralgias, myalgias, hematuria, non IgE-mediated anaphylaxis) at Days 1, 3, 7, and 28 post-transfusion.
DAYS 1, 3, 7, AND 28
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get covid-19 a year in the United States?

1 in 3 people get the virus a year in the United States. Most of those have no signs or symptoms but if you have one or more risk factors, you are much more likely to get this pneumonia.

Anonymous Patient Answer

Can covid-19 be cured?

Without any intervention, the disease can continue to circulate and become more contagious. In China, the total case number of 2019-nCoV infection in December, 2019 was about 3.6 million people with almost 7.4 million illness cases (i.e. 1.5 million case-fatalities). Of those, around one third of total case (i. e., more than 3.6 million) remained latent for 6 months.

Anonymous Patient Answer

What causes covid-19?

Covid-19 virus has a wide geographical distribution. It is spread by droplet and fomite transmission. It is mostly harmless, but a new strain can have a severe global impact. Some of the mortality rates are from symptom-related death rates.

Anonymous Patient Answer

What are the signs of covid-19?

There should be some degree of pain and fever in all cases. Signs of more severe disease include, in addition to the above,: cough, fatigue, loss of appetite, nausea, and vomiting. There is also risk of complications such as pneumonia and myocarditis: these will be discussed later in text (Section 9.

Anonymous Patient Answer

What is covid-19?

This outbreak has contributed to a better understanding of the transmission and epidemiology of the disease. Effective surveillance and containment measures will help to halt the outbreak. As such, the current situation will require a long-term approach for controlling, monitoring and controlling the effects of the outbreak. Furthermore, surveillance systems to detect or anticipate future outbreaks will assist in improving outbreak management and preparedness plans.

Anonymous Patient Answer

What are common treatments for covid-19?

There are no specific treatment for covid-19 yet, but many people still find themselves in contact with others who may be infected. People with co-existing conditions should consult their GP for information about their specific conditions and treatment. Some people may take time to recover from or cope with the initial symptoms of covid-19, and so should also be advised to take time off work and seek counselling or help if necessary.

Anonymous Patient Answer

What are the common side effects of covid convalescent plasma?

The common CPP side effects were consistent with those for CPP used for other applications and of general clinical experience. Further, CPP does not contain potential infectious disease agents, biologics, or other medications known to cause adverse effects and must be considered as a potential therapy for individuals at high risk for possible coronavirus-associated illnesses.

Anonymous Patient Answer

What is covid convalescent plasma?

Covid is convalescent plasma for a coronavirus to stop the spread of disease. Covid is a subset of plasma derived from recovered convalescent donors who have antibodies for coronaviruses which were found in their blood or secretions. Covid convalescent plasma is sourced in a similar way to human plasma but it is not made using human blood products. There are three types of serum used in plasma therapy: serum from healthy donors and plasma derived from plasma donors. Plasma from plasma donors was used in the plasma therapies for SARS virus and for the SARS coronavirus outbreak in 2002. In 2018, plasma from plasma donors was used for the first SARS outbreak.

Anonymous Patient Answer

Is covid convalescent plasma safe for people?

We could not demonstrate in this small series that PRP was superior to plasma alone in terms of effectiveness for the clinical endpoint (95% confidence interval 0.95 to 1.22). However, given the limited sample size of our study, a larger trial might show an effect of PRP on clinical outcomes. Larger studies have the potential to define what role PRP can potentially play in the convalescent phase of the disease course. Given the risks of administering vaccines during the peak influenza season and the urgent need for a plasma-based strategy to meet this gap, in this paper we propose PRP as a means of preserving immunity at least during the immediate post-influenza vaccination period.

Anonymous Patient Answer

What is the average age someone gets covid-19?

The average age someone gets infected with coronavirus (COVID-19) is 66 years in the United States, 56 years in Germany, 50 years in Argentina, and 45 years in India. The average age someone has the disease is 70 years in the United States, 61 years in Germany, and 58 years in Switzerland. [The age average in China is around 50 years] (https://www.cdc.gov/coronavirus/).

Anonymous Patient Answer

How does covid convalescent plasma work?

We confirmed that covid plasma can be used in the ICU to reduce the risk of developing secondary pneumonia in patients with SARS, MERS, or H1N1. We also suggested that the mechanism of action in these settings involves antibodies and IFN-γ. These observations help in the development of potential antiviral therapy for patients with a confirmed infection. In future, we plan to translate our data to clinical trials. This paper has presented a new antiviral intervention for patients with severe disease in this public health crisis.

Anonymous Patient Answer

Who should consider clinical trials for covid-19?

The impact on the NHS is substantial and most of patients who could benefit are being overlooked. Trials evaluating vaccines in high risk groups such as people with a known or suspected coronavirus infection are critical to assess any potential benefits. Many have already been started and may be running late as the number of trials continues to increase. There are several challenges that are being explored in these trials, including the use of multiple antiviral agents in an attempt to tackle the virus, the optimal timing and dosage of these multiple antiviral therapies, and use of a placebo as a means to address any bias related to treatment. Clinical trials are urgently needed for all patients, to further our understanding of the virus and allow more effective treatment options.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for COVID-19 by sharing your contact details with the study coordinator.